Study of OZURDEX® in the Treatment of Diabetic Macular Oedema (DME) in Australia - The AUSSIEDEX Study

Allergan

Status: Completed

Conditions: Diabetic Macular Oedema

Treatments: Drug: dexamethasone intravitreal implant

Study type: Observational

Funder types: Industry

Identifiers

NCT02731911

CMO-AP-EYE-0438

Details and patient eligibility

About

This prospective study will assess Ozurdex in the treatment of Diabetic Macular Oedema in clinical practice.

Enrollment: 202 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Pseudophakic or phakic and scheduled for a cataract operation
• Macular oedema due to DME

Exclusion criteria

• Previous Ozurdex® treatment

Trial design

202 participants in 1 patient group

Ozurdex® (dexamethasone intravitreal implant)

Description:

Patients who received Ozurdex® in the treatment of Diabetic Macular Oedema per local standard of care in clinical practice.

Treatment:

Drug: dexamethasone intravitreal implant